Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy

Affiliations

¹ Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Review

Konstantinos Papamichael et al. Am J Gastroenterol. 2017 May.

. 2017 May;112(5):673-676.

doi: 10.1038/ajg.2017.21. Epub 2017 Feb 21.

¹ Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

No abstract available

Comment in

Response to Reinink.
Papamichael K, Cheifetz AS. Papamichael K, et al. Am J Gastroenterol. 2017 Dec;112(12):1893-1894. doi: 10.1038/ajg.2017.375. Am J Gastroenterol. 2017. PMID: 29215625 No abstract available.
A Pharmacokinetic Rationale for Proactive Therapeutic Drug Monitoring of Anti-TNF Drugs.
Reinink AR. Reinink AR. Am J Gastroenterol. 2017 Dec;112(12):1892-1893. doi: 10.1038/ajg.2017.266. Am J Gastroenterol. 2017. PMID: 29215627 No abstract available.